Understand what your gut health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
A functional read on your gut's detox recycling enzyme
The beta-glucuronidase capacity test analyzes a stool sample to measure the activity of beta-glucuronidase, an enzyme produced by certain gut microbes that can “unpack” compounds your liver has tagged for removal. In the lab, this is typically quantified with a colorimetric or fluorometric assay and reported per gram of stool. Some platforms also infer capacity by identifying microbial genes (like gus) through sequencing. Results reflect a functional snapshot of your current gut ecosystem, not a fixed trait.
Why this matters: your liver neutralizes hormones, bile acids, and many drugs by attaching glucuronic acid so they can be excreted. Gut beta-glucuronidase can remove that tag, reactivating those compounds and sending them back into circulation through the enterohepatic route. This enzyme therefore sits at the crossroads of digestion, inflammation, medication response, and hormone balance. Science here is evolving, but consistent themes include the importance of microbial diversity, diet quality, and stability over time. Your result is most meaningful when interpreted alongside symptoms, medication history, and other biomarkers.
Where this enzyme touches real-world symptoms
Beta-glucuronidase connects your microbiome to real-world health questions. Elevated capacity can increase reactivation of estrogens and certain bile acids, which may contribute to patterns like cyclic breast tenderness or stool urgency after fatty meals in some people, while very low capacity often reflects recent antibiotics or low microbial diversity. Testing can help contextualize persistent bloating, gas, stool changes, skin flares, or sensitivity to specific medications that rely on glucuronidation. It also helps you see how restrictive diets, alcohol, or chronic stress may be shaping your gut’s functional output. Situations where this snapshot is particularly informative include after antibiotic courses, during major diet changes, or when investigating hormone-related concerns with a clinician.
Zooming out, the gut microbiome influences inflammation, glucose regulation, barrier integrity, and even mood through the gut–brain axis. Tracking beta-glucuronidase over time can show whether nutrition shifts, fiber diversity, probiotic use, or stress recovery are nudging your gut toward a more resilient pattern. The goal is not a single “perfect” number, but pattern recognition: understanding how your unique microbiome manages hormone recycling and xenobiotic processing, and using that insight to guide preventive care and long-term wellness with your care team.
Interpreting high, low, and balanced activity
Your report typically shows beta-glucuronidase activity relative to a reference population. Think of this as a functional readout of how actively your microbes are deconjugating compounds your liver has prepared for removal. In general, balanced microbiomes show moderate enzyme activity and higher overall diversity with beneficial genera represented. Very high activity can point to a microbiome inclined to reactivate estrogens, bile acids, and some drugs; very low activity can reflect suppressed microbial function after antibiotics, acute illness, or a narrow diet. “Normal” spans a range and is shaped by context such as diet, geography, and age.
When activity lands in a balanced zone, it usually aligns with efficient digestion, healthy short-chain fatty acid production, steadier inflammatory signaling, and a stable gut barrier. In this state, the liver’s glucuronidation (UGT) pathways and microbial deconjugation are in a workable equilibrium, so compounds are inactivated and eliminated at a reliable pace. Optimal ranges vary, and a single result should be interpreted relative to your baseline and other labs.
When results point to imbalance, the pattern is interpretive, not diagnostic. Higher-than-reference activity can coincide with reduced microbial diversity, diets lower in fiber, or blooms of species known to carry beta-glucuronidase genes, and it may contribute to increased reabsorption of estrogens or irritation from certain bile acids. Lower-than-reference activity can follow antibiotics or bowel prep, or reflect a microbiome with fewer enzyme-producing species. These are signals to explore mechanisms with your clinician and dietitian rather than conclusions on their own. In practical terms, discussions often focus on fiber diversity and fermented foods, evaluating alcohol and ultra-processed intake, reviewing medications that depend on glucuronidation, and considering broader microbiome patterns, though more research is needed to define targets.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Inputs that sway the beta-glucuronidase capacity read
Context and limitations matter. Stool water content, recent diarrhea or constipation, colonoscopy prep, probiotics, and antibiotics can all shift measured activity. Assay methods differ across labs, so absolute values are not interchangeable. Day-to-day variation exists, which is why trends across time are more informative than a single snapshot. Life stage can also influence interpretation: pregnancy alters bile acid and hormone handling; perimenopause changes estrogen dynamics; and children have developing microbiomes with different reference norms. If you are tracking hormone-related concerns, pairing this test with a clinical hormone panel and liver enzymes can clarify the bigger picture. Taken together with your history, diet, symptoms, and other biomarkers, a beta-glucuronidase capacity result can help personalize strategies for digestion, energy, and long-term health optimization while staying grounded in current evidence.
Frequently Asked Questions
References
- Pollet RM, D'Agostino EH, Walton WG, Xu Y, Little MS, Biernat KA, Pellock SJ, Patterson LM, Creekmore BC, Isenberg HN, Bahethi RR, Bhatt AP, Liu J, Gharaibeh RZ, Redinbo MR (2017). An atlas of β-glucuronidases in the human intestinal microbiome. *Structure*, *25*(7), 967-977.e5. https://doi.org/10.1016/j.str.2017.05.003
- Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (2016). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. *Cell*, *165*(6), 1332-1345. https://doi.org/10.1016/j.cell.2016.05.041
- Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A (2021). Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. *Scientific Reports*, *11*, 3030. https://doi.org/10.1038/s41598-021-82726-y
- Lynch SV, Pedersen O (2016). The human intestinal microbiome in health and disease. *The New England Journal of Medicine*, *375*(24), 2369-2379. https://doi.org/10.1056/NEJMra1600266
- Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, Gasbarrini A, Segata N, Cammarota G (2025). International consensus statement on microbiome testing in clinical practice. *The Lancet Gastroenterology & Hepatology*, *10*(2), 154-167. https://doi.org/10.1016/S2468-1253(24)00311-X















